Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
E. Wang, A. A. Cohen, L. F. Caldera, J. R. Keeffe, A. V. Rorick, Y. M. Aida, P. N. P. Gnanapragasam, P. J. Bjorkman, A. K. Chakraborty
The paper designs mosaic nanoparticles with SARS-like betacoronavirus RBDs to enhance cross-reactive immune responses in mice, finding that mosaic-7COM elicits stronger responses against zoonotic sarbecoviruses and Omicrons.
bioRxiv · Feb 28, 2024Immunology
A. A. Cohen, J. R. Keeffe, A. Schiepers, S. E. Dross, A. J. Greaney, A. V. Rorick, H. Gao, P. N. P. Gnanapragasam, C. Fan, A. P. West, A. I. Ramsingh, J. H. Erasmus, J. D. Pata, H. Muramatsu, N. Pardi, , P. J. Bjorkman
The paper shows mosaic-8b nanoparticles induce broader cross-reactive antibodies than homotypic ones, even in pre-vaccinated animals, suggesting potential for improved vaccine design against emerging sarbecoviruses.
bioRxiv · Feb 8, 2024Immunology
H. B. Gristick, H. Hartweger, M. Loewe, J. van Schooten, V. Ramos, T. Y. Oliviera, Y. Nishimura, N. S. Koranda, A. Wall, K.-H. Yao, D. Poston, A. Gazumyan, M. Wiatr, M. Horning, J. R. Keeffe, , P. J. Bjorkman
This study shows that CD4bs immunogens can elicit potent, broad anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals.
bioRxiv · Sep 8, 2022Immunology
C. Fan, A. A. Cohen, M. Park, A. F.-H. Hung, J. R. Keeffe, P. N. Gnanapragasam, Y. E. Lee, L. M. Kakutani, Z. Wu, K. E. Malecek, J. C. Williams, P. J. Bjorkman
This study identifies cross-reactive monoclonal antibodies against conserved sarbecovirus epitopes using mosaic RBD nanoparticles and shows their neutralization potential against SARS-CoV-2 variants and animal sarbecoviruses.
bioRxiv · Jun 28, 2022Immunology
A. A. Cohen, N. A. van Doremalen, A. J. Greaney, H. Andersen, A. Sharma, T. N. Starr, J. R. Keeffe, C. Fan, J. E. Schulz, P. N. P. Gnanapragasam, L. M. Kakutani, A. P. West, G. Saturday, Y. E. Lee, H. Gao, , P. J. Bjorkman
This study designs mosaic RBD nanoparticles to elicit antibodies against conserved sarbecovirus epitopes, showing broader protection against SARS-CoV-2 variants and animal sarbecoviruses in animal models.
bioRxiv · Mar 25, 2022 · PreprintMicrobiology
C. A. Jette, A. A. Cohen, P. N. P. Gnanapragasam, F. Muecksch, Y. E. Lee, K. E. Huey-Tubman, F. Schmidt, T. Hatziioannou, P. D. Bieniasz, M. C. Nussenzweig, A. P. West, J. R. Keeffe, P. Bjorkman, C. O. Barnes
The paper identifies two class 4 anti-RBD antibodies from COVID-19 donors that broadly neutralize zoonotic sarbecoviruses and SARS-CoV-2 variants with high potency.
bioRxiv · Apr 23, 2021Immunology
M. E. Abernathy, H. B. Gristick, J. Vielmetter, J. R. Keeffe, P. N. Gnanapragasam, Y. E. Lee, A. Escolano, R. Gautam, M. S. Seaman, M. A. Martin, M. C. Nussenzweig, P. J. Bjorkman
This study identifies an off-target antibody that displaces the HIV-1 Env fusion peptide and blocks neutralizing epitopes, providing insights for vaccine design.
bioRxiv · Mar 17, 2021Immunology
A. A. Cohen, P. N. P. Gnanapragasam, Y. E. Lee, S. Ou, L. M. Kakutani, J. R. Keeffe, C. O. Barnes, H.-J. Wu, M. Howarth, A. P. West, M. C. Nussenzweig, P. J. Bjorkman
The paper demonstrates that mosaic nanoparticles displaying multiple coronavirus RBDs induce cross-reactive and neutralizing antibodies against SARS-CoV-2 and zoonotic coronaviruses in mice.
bioRxiv · Nov 17, 2020Immunology